Bold opening: GLP-1 weight loss drugs aren’t magic bullets — the World Health Organization just released guidance that reframes how they should be used and what they can and cannot do. Here’s what you need to know, explained clearly and with practical context.
The World Health Organization has published new guidance on GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound, framing them as tools to address obesity — a significant global health challenge. A 2024 poll indicated about one in eight American adults had tried a GLP-1 drug, and the share with prescriptions appears to be rising. The WHO guidance highlights two main conditional recommendations for using these drugs.
First recommendation: GLP-1s can be used to treat obesity in adults, with the exception of pregnant women. This is labeled as conditional because long-term data on these relatively new therapies remains limited. Questions remain about what happens when people stop taking the drugs and how outcomes look with extended use. A notable concern is cost: taking GLP-1 medications indefinitely can create a substantial financial burden for many patients.
GLP-1 drugs are usually administered as a weekly injection. They work by influencing hormones that regulate appetite, helping people feel fuller sooner. Although manufacturers Novo Nordisk (makers of Ozempic and Wegovy) and Eli Lilly (makers of Mounjaro and Zepbound) have announced some price reductions recently, a monthly course of the weight-loss medications still costs hundreds of dollars at best.
Second recommendation: GLP-1s are not a universal cure. They should be viewed as a component of a broader obesity-management strategy. For best results, individuals should combine medication use with intensive changes to diet and physical activity. As Dr. Francesca Celletti, WHO senior advisor for obesity, emphasized, “Medicine alone will not solve the problem.”
This perspective aligns with existing research stressing the importance of adequate nutrition even when medications help restrain portion sizes. GLP-1s can sometimes lead to muscle mass loss, which underscores the value of regular exercise and strength training alongside treatment.
Beyond individual treatment, the WHO underscores that obesity is a societal issue requiring collective action. Prevention remains essential, and it would be misguided to assume medications alone can resolve the problem. Dr. Karen Sealey, director of the Healthy Caribbean Coalition and the Inter-American Heart Foundation, cautions against ignoring prevention or assuming pharmacotherapy alone can fix the situation.
In summary, the new guidance positions GLP-1 drugs as helpful components within a broader obesity-management framework, with careful attention to long-term effects, cost considerations, and the necessity of concurrent lifestyle interventions and population-level prevention efforts.
